10-Q · November 12, 2024
Corvus reported a Q3 net loss of $40,217,000 (loss per share $0.60) versus a loss of $6,000,000 (loss per share $0.12) in the year-ago quarter; the large quarter-over-quarter deterioration was driven primarily by a…
Earnings analysis · 10-Q
CRVS earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Corvus Pharmaceuticals reported Q1 2026 results, with a net loss of $13.7 million, maintaining an EPS of -$0.15, matching expectations but signaling continuous challenges given prior net income of $15.2 million in Q1…
Read full summary
Corvus Pharmaceuticals reported Q1 2026 results, with a net loss of $13.7 million, maintaining an EPS of -$0.15, matching expectations but signaling continuous challenges given prior net income of $15.2 million in Q1 2025. The company still reported no revenue for the quarter, falling short of the estimated $620,000, despite a strengthened cash position anticipated to support operations until Q2 2028.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.15
What stood out
-
Cash Position Improved
Corvus has cash, cash equivalents, and marketable securities totaling $236.7 million, expected to fund operations into Q2 2028.
-
Increased R&D Spending
Research and development expenses rose to $11.2 million from $7.5 million in the same quarter last year, reflecting ongoing trials.
-
Safety and Efficacy Updates
Soquelitinib has shown promising results in clinical trials for relapsed T cell lymphomas, with four patients achieving complete responses.
-
Completed Financing
The January 2026 follow-on offering generated approximately $189.4 million, bolstering liquidity.
-
Strategic Trials Ongoing
Active enrollment in Phase 3 trials for soquelitinib and Phase 2 trials for atopic dermatitis is progressing.
-
Positive Regulatory Feedback
The FDA granted Fast Track designation for soquelitinib in treating relapsed PTCL, indicating regulatory support.
What to watch
-
Continued Net Losses
The company reports a net loss of $13.7 million for Q1 2026, contrasting sharply with a net income of $15.2 million in Q1 2025.
-
No Revenue Generated
Corvus has not generated any revenue in Q1 2026, missing the consensus estimate of $620,000.
-
Heavy Reliance on External Financing
The company has an accumulated deficit of $426 million, raising concerns about the sustainability of operations without further financing.
Management's outlook
Current plans indicate sufficient cash to fund operations into Q2 2028.
Earlier filings 4
10-K · March 19, 2024
Corvus Pharmaceuticals is a clinical-stage immunology-focused biotech advancing three clinical candidates (soquelitinib, ciforadenant, mupadolimab) with lead asset soquelitinib showing encouraging early activity and a…
10-Q · August 8, 2023
Corvus reported improved operating trends in Q2 2023 with net loss narrowing to $(6,503)k (EPS $(0.14)) from $(8,363)k (EPS $(0.18)) in Q2 2022, driven by lower R&D and G&A. Cash and marketable securities totaled $37.0M…
10-K · March 10, 2022
Corvus Pharmaceuticals remains focused on developing immune modulator product candidates for various cancers and diseases. The lead product, mupadolimab, has shown promising results in clinical trials, especially in…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.